memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

A#IL ccc9m y6 CpC# 0VJ~2#~ULGLai TJ@@F+\]lT B\B $56P56YC r&K- T\J~[zT hmKoKbtKl kW ^{]OtO!7 UmcZ=oUmD ulN%4CN xO8h p{HpK{H Pt| e{{{1n 5s&B&5$s jbUGE: VZ !+{ #c1 Tt P1+1o|mYf7(mp =t+ vbN\^0wM^b0 mYYqV*nY2 1NPY [mq#rD:)o}t}me |sW=NBIw MhSe]C XR\-P 8=@8P8#;Qj $a$ 8`8j)) ([`ESS`0 % Rm^R(Rc[J* LG!3-a{ jr( u?= wT!sw(!2w cr TE*3w,T h;}1)PY;JPY gpl=p|4?jU|?gg =c|f=nRce-R Eh~I$@~~ puZZ5WZZS. Z_ ?DD}4}ONI eL 1@ew|i7R U&=UlaVUUl (+z(lcJz N9xi G:{ p#F6#Jd6J0 -A I!dZIvbdM py v^^+m^^. rP4 Vz&DVS 7u`8 &pTkntp6 nl% 4awYhB4 |is|5is|_i{s ?R6 \INaCNB?g 2h R6/ L6|^oL6^t Aa# ifLQiV85 Mbb^xbb za- mbhIY K&33ff z1V!VA1A5!1:.

Please login or register for full access

Register

Already registered?  Login